Biblio
Primary graft failure following allogeneic hematopoietic stem cell transplantation: risk factors, treatment and outcomes. Hematology. 2022;27(1):293-299.
Refractory patients with favorable/intermediate-risk acute myeloid leukemia benefit from azacytidine maintenance therapy following allogeneic hematopoietic stem cell transplantation. Hematol Oncol. 2023.
Sorafenib therapy is associated with improved outcomes for FLT3-ITD AML relapsing after allo-HSCT. Biol Blood Marrow Transplant. 2019.